Stockreport

Recursion gets FDA approval to begin phase 1 trials of AI-discovered cancer treatment [CNBC]

Exscientia Plc - American Depositary Shares  (EXAI) 
PDF Recursion was able to use its artificial intelligence-enabled drug discovery platform to identify an area of biology to target for the treatment of solid tumors and lym [Read more]